Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.
Saved in:
| Title: | Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. |
|---|---|
| Authors: | Gonzalez-Angulo AM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lei X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Alvarez RH; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Green MC; Genentech, South San Francisco, CA., Murray JL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Valero V; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Koenig KB; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ibrahim NK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Nair L; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Krishnamurthy S; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fmeric@mdanderson.org. |
| Source: | Clinical breast cancer [Clin Breast Cancer] 2015 Oct; Vol. 15 (5), pp. 325-31. Date of Electronic Publication: 2015 Mar 24. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 25913905 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gonzalez-Angulo+AM%22">Gonzalez-Angulo AM</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Lei+X%22">Lei X</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Alvarez+RH%22">Alvarez RH</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Green+MC%22">Green MC</searchLink>; Genentech, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Murray+JL%22">Murray JL</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Valero+V%22">Valero V</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Koenig+KB%22">Koenig KB</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Ibrahim+NK%22">Ibrahim NK</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Litton+JK%22">Litton JK</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Nair+L%22">Nair L</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Krishnamurthy+S%22">Krishnamurthy S</searchLink>; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Hortobagyi+GN%22">Hortobagyi GN</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fmeric@mdanderson.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100898731%22">Clinical breast cancer</searchLink> [Clin Breast Cancer] 2015 Oct; Vol. 15 (5), pp. 325-31. <i>Date of Electronic Publication: </i>2015 Mar 24. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100898731 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0666 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215268209%22">15268209 </searchLink><i>NLM ISO Abbreviation: </i>Clin Breast Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25913905 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clbc.2015.03.004 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 325 Titles: – TitleFull: Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gonzalez-Angulo AM – PersonEntity: Name: NameFull: Lei X – PersonEntity: Name: NameFull: Alvarez RH – PersonEntity: Name: NameFull: Green MC – PersonEntity: Name: NameFull: Murray JL – PersonEntity: Name: NameFull: Valero V – PersonEntity: Name: NameFull: Koenig KB – PersonEntity: Name: NameFull: Ibrahim NK – PersonEntity: Name: NameFull: Litton JK – PersonEntity: Name: NameFull: Nair L – PersonEntity: Name: NameFull: Krishnamurthy S – PersonEntity: Name: NameFull: Hortobagyi GN – PersonEntity: Name: NameFull: Meric-Bernstam F IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2015 Oct Type: published Y: 2015 Identifiers: – Type: issn-electronic Value: 1938-0666 Numbering: – Type: volume Value: 15 – Type: issue Value: 5 Titles: – TitleFull: Clinical breast cancer Type: main |
| ResultId | 1 |
